Nazila Fathi Maroufi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nazila Fathi Maroufi has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Vahid Vahedian
Cancer Biology Research Group, Faculty of Medicine Institute of Biotechnology (FMB-IBTEC) Sao Paulo State University (UNESP), Brazil
4 shared publications - Mohammad Nouri
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications Vahid Vahedian
Division of Hematology and Cellular Therapy/LIM-31, Department of Internal Medicine, Faculty of Medicine, Clinical Hospital, University of São Paulo, São Paulo, Brazil
3 shared publicationsYousef Faridvand
Stem Cell and Regenerative Medicine Institute , Tabriz University of Medical Sciences , Tabriz , Iran
3 shared publicationsAlireza Isazadeh
Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran
2 shared publications- Alireza Isazadeh
Department of Genetic , Tabriz Branch, Islamic Azad University , Tabriz , Iran
2 shared publications
Latest Publications
- 5 February 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (2) , e70726
Exosome‐Derived Circular RNAs in Colorectal Cancer: Emerging Roles in Tumorigenesis, Diagnosis, and Therapy
Circular RNAs (circRNAs) are a class of non‐coding RNAs characterized by their covalently closed loop structures, which confer remarkable stability. Recent studies have highlighted the role of exosomal circRNAs, which are encapsulated within extracellular vesicles known as exosomes, in intercellular communication and tumor progression. In colorectal cancer (CRC), exosomal circRNAs have been implicated in various oncogenic processes, including cell proliferation, migration, invasion, epithelial‐mesenchymal transition (EMT), and drug resistance. These molecules exhibit dysregulated expression patterns in CRC tissues and bodily fluids, making them promising candidates for non‐invasive biomarkers. Moreover, their functional roles in modulating signaling pathways and the tumor microenvironment suggest their potential therapeutic applications. This review summarizes our current understanding of exosomal circRNA biology, highlights their roles in the CRC development and progression, and discusses their clinical significance as diagnostic, prognostic and therapeutic tools.
- 5 February 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (2) , e70726
Exosome‐Derived Circular RNAs in Colorectal Cancer: Emerging Roles in Tumorigenesis, Diagnosis, and Therapy
Circular RNAs (circRNAs) are a class of non‐coding RNAs characterized by their covalently closed loop structures, which confer remarkable stability. Recent studies have highlighted the role of exosomal circRNAs, which are encapsulated within extracellular vesicles known as exosomes, in intercellular communication and tumor progression. In colorectal cancer (CRC), exosomal circRNAs have been implicated in various oncogenic processes, including cell proliferation, migration, invasion, epithelial‐mesenchymal transition (EMT), and drug resistance. These molecules exhibit dysregulated expression patterns in CRC tissues and bodily fluids, making them promising candidates for non‐invasive biomarkers. Moreover, their functional roles in modulating signaling pathways and the tumor microenvironment suggest their potential therapeutic applications. This review summarizes our current understanding of exosomal circRNA biology, highlights their roles in the CRC development and progression, and discusses their clinical significance as diagnostic, prognostic and therapeutic tools.
- Open Access
- 1 August 2025
- Published by Negah Scientific Publisher in Research in Molecular Medicine
- Vol. 13 (3) , 141-152
Apatinib as a Potential Therapeutic Agent in Breast Cancer Treatment With a Focus on Clinical Trials: A State-of-the-art Study
Breast cancer is the most common cancer in females. The treatment of this cancer is one of the challenges facing the world’s health system. Metastasis and cancer cell invasion are the reasons for the difficulty in treating this cancer. Also, the formation of new blood vessels, or angiogenesis, facilitates metastasis ...
- 1 August 2025
- Published by Negah Scientific Publisher in Research in Molecular Medicine
- Vol. 13 (3) , 141-152
Open AccessApatinib as a Potential Therapeutic Agent in Breast Cancer Treatment With a Focus on Clinical Trials: A State-of-the-art Study
Breast cancer is the most common cancer in females. The treatment of this cancer is one of the challenges facing the world’s health system. Metastasis and cancer cell invasion are the reasons for the difficulty in treating this cancer. Also, the formation of new blood vessels, or angiogenesis, facilitates metastasis ...
- 2 September 2024
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 24 (5) , 1-24
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view
MicroRNAs (miRNAs) are a group of small non-coding RNAs and play an important role in controlling vital biological processes, including cell cycle control, apoptosis, metabolism, and development and differentiation, which lead to various diseases such as neurological, metabolic disorders, and cancer. Chemotherapy consider as gold treatment approaches for cancer patients. However, chemotherapeutic is one of the main challenges in cancer management. Doxorubicin (DOX) is an anti-cancer drug that interferes with the growth and spread of cancer cells. DOX is used to treat various types of cancer, including breast, nervous tissue, bladder, stomach, ovary, thyroid, lung, bone, muscle, joint and soft tissue cancers. Also recently, miRNAs have been identified as master regulators of specific genes responsible for the mechanisms that initiate chemical resistance. miRNAs have a regulatory effect on chemotherapy resistance through the regulation of apoptosis process. Also, the effect of miRNAs p53 gene as a key tumor suppressor was confirmed via studies. miRNAs can affect main biological pathways include PI3K pathway. This review aimed to present the current understanding of the mechanisms and effects of miRNAs on apoptosis, p53 and PTEN/PI3K/Akt signaling pathway related to DOX resistance. Graphical Abstract miRNAs involve in DOX resistance according to effecting pathways.
- 2 September 2024
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 24 (5) , 1-24
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view
MicroRNAs (miRNAs) are a group of small non-coding RNAs and play an important role in controlling vital biological processes, including cell cycle control, apoptosis, metabolism, and development and differentiation, which lead to various diseases such as neurological, metabolic disorders, and cancer. Chemotherapy consider as gold treatment approaches for cancer patients. However, chemotherapeutic is one of the main challenges in cancer management. Doxorubicin (DOX) is an anti-cancer drug that interferes with the growth and spread of cancer cells. DOX is used to treat various types of cancer, including breast, nervous tissue, bladder, stomach, ovary, thyroid, lung, bone, muscle, joint and soft tissue cancers. Also recently, miRNAs have been identified as master regulators of specific genes responsible for the mechanisms that initiate chemical resistance. miRNAs have a regulatory effect on chemotherapy resistance through the regulation of apoptosis process. Also, the effect of miRNAs p53 gene as a key tumor suppressor was confirmed via studies. miRNAs can affect main biological pathways include PI3K pathway. This review aimed to present the current understanding of the mechanisms and effects of miRNAs on apoptosis, p53 and PTEN/PI3K/Akt signaling pathway related to DOX resistance. Graphical Abstract miRNAs involve in DOX resistance according to effecting pathways.
- 23 July 2024
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 45 (3) , 119-130
The evaluation of melatonin and EGF interaction on breast cancer metastasis
Objectives: Metastasis in breast cancer is the first cause of death in patients. The epidermal growth factor (EGF) increases cancer cells’ invasion, and migration. Melatonin’s inhibitory effects on various types of cancer were confirmed. This study aimed to investigate whether melatonin could apply its impact through the EGF-related pathways or not. Methods: First, MDA-MB-231 and MCF7 cells were cultured, and then melatonin effects on cell viability were determined by MTT assay. Transwell invasion assay was applied to identify the invasiveness of these breast cancer cell lines under treatment of EGF and melatonin. Real-time RT-PCR then investigated the expression of MMP9 and MMP2 in determined groups. Cell proliferation was also assayed under EGF and melatonin treatment using Ki67 assessment by flow cytometry. Results: The rate of invasion and migration of EGF-treated cells increased in both groups, in which melatonin caused increased invasion by EGF just in MCF7 cells. MMP9 and MMP2 expression increased significantly in both cell lines under EGF treatment, and melatonin increased these genes’ expression in both cell lines (p<0.05). EGF increased the MMP9 and MMP2 gene expression, and melatonin increased EGF-induced expression (p<0.05). The EGF reduced the expression of the Ki67 protein in the MCF7 cell line, which was negatively affected by melatonin and EGF. In contrast, along with melatonin, EGF did not affect the proliferation of the MDA-MB-231 cell line. Conclusions: The results of this study show that melatonin in the presence of EGF does not show the anti-cancer properties previously described for this substance.
- 23 July 2024
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 45 (3) , 119-130
The evaluation of melatonin and EGF interaction on breast cancer metastasis
Objectives: Metastasis in breast cancer is the first cause of death in patients. The epidermal growth factor (EGF) increases cancer cells’ invasion, and migration. Melatonin’s inhibitory effects on various types of cancer were confirmed. This study aimed to investigate whether melatonin could apply its impact through the EGF-related pathways or not. Methods: First, MDA-MB-231 and MCF7 cells were cultured, and then melatonin effects on cell viability were determined by MTT assay. Transwell invasion assay was applied to identify the invasiveness of these breast cancer cell lines under treatment of EGF and melatonin. Real-time RT-PCR then investigated the expression of MMP9 and MMP2 in determined groups. Cell proliferation was also assayed under EGF and melatonin treatment using Ki67 assessment by flow cytometry. Results: The rate of invasion and migration of EGF-treated cells increased in both groups, in which melatonin caused increased invasion by EGF just in MCF7 cells. MMP9 and MMP2 expression increased significantly in both cell lines under EGF treatment, and melatonin increased these genes’ expression in both cell lines (p<0.05). EGF increased the MMP9 and MMP2 gene expression, and melatonin increased EGF-induced expression (p<0.05). The EGF reduced the expression of the Ki67 protein in the MCF7 cell line, which was negatively affected by melatonin and EGF. In contrast, along with melatonin, EGF did not affect the proliferation of the MDA-MB-231 cell line. Conclusions: The results of this study show that melatonin in the presence of EGF does not show the anti-cancer properties previously described for this substance.
- Open Access
- 21 February 2023
- Published by Elsevier in Toxicology Reports
- Vol. 10, 436-440
Xanthomicrol: Effective therapy for cancer treatment
- 21 February 2023
- Published by Elsevier in Toxicology Reports
- Vol. 10, 436-440
Open AccessXanthomicrol: Effective therapy for cancer treatment
- Open Access
- 20 June 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113297
An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin
- 20 June 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113297
Open AccessAn evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin
- 28 January 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 231, 153783
The role of SOX family in cancer stem cell maintenance: With a focus on SOX2
- 28 January 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 231, 153783
The role of SOX family in cancer stem cell maintenance: With a focus on SOX2
- 17 November 2021
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 43 (1) , 7-14
Effect of Auraptene on angiogenesis in Xenograft model of breast cancer
Objectives: Angiogenesis is the most important challenge in breast cancer treatment. Recently, scientists become interesting in rare natural products and intensive researches was performed to identify their pharmacological profile. Auraptene shows helpful effects such as cancer chemo-preventive, anti-inflammatory, anti-oxidant, immuno-modulatory. In this regard, we investigated the anti-angiogenesis effect of Auraptene in in-vitro and in-vivo model of breast cancer. Methods: In this study, 4T, MDA-MB-231 and HUVEC cell lines were used. The proliferation study was done by MTT assay. For tube formation assay, 250 matrigel, 1 × 10 4 HUVEC treated with Auraptene, 20 ng/mL EGF, 20 ng/mL bFGF and 20 ng/mL VEGF were used. Gene expression of important gene related to angiogenesis in animal model of breast cancer was investigated by Real-time PCR. Protein expression of VCAM-1 and TNFR-1 gene related to angiogenesis in animal model of breast cancer was investigated by western-blot. Results: Auraptene treatment led to reduction in cell viability of MDA-MB-231 in a concentration-dependent manner. Also, we observed change in the number of tubes or branches formed by cells incubated with 40 and 80 μM Auraptene. Auraptene effect the gene expression of important gene related to angiogenesis (VEGF, VEGFR2, COX2, IFNɣ). Moreover, the western blot data exhibited that Auraptene effect the protein expression of VCAM-1 and TNFR-1. Conclusions: Overall, this study shows that Auraptene significantly suppressed angiogenesis via down-regulation of VEGF, VEGFR2, VCAM-1, TNFR-1, COX-2 and up-regulation of IFNγ.
- 17 November 2021
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 43 (1) , 7-14
Effect of Auraptene on angiogenesis in Xenograft model of breast cancer
Objectives: Angiogenesis is the most important challenge in breast cancer treatment. Recently, scientists become interesting in rare natural products and intensive researches was performed to identify their pharmacological profile. Auraptene shows helpful effects such as cancer chemo-preventive, anti-inflammatory, anti-oxidant, immuno-modulatory. In this regard, we investigated the anti-angiogenesis effect of Auraptene in in-vitro and in-vivo model of breast cancer. Methods: In this study, 4T, MDA-MB-231 and HUVEC cell lines were used. The proliferation study was done by MTT assay. For tube formation assay, 250 matrigel, 1 × 10 4 HUVEC treated with Auraptene, 20 ng/mL EGF, 20 ng/mL bFGF and 20 ng/mL VEGF were used. Gene expression of important gene related to angiogenesis in animal model of breast cancer was investigated by Real-time PCR. Protein expression of VCAM-1 and TNFR-1 gene related to angiogenesis in animal model of breast cancer was investigated by western-blot. Results: Auraptene treatment led to reduction in cell viability of MDA-MB-231 in a concentration-dependent manner. Also, we observed change in the number of tubes or branches formed by cells incubated with 40 and 80 μM Auraptene. Auraptene effect the gene expression of important gene related to angiogenesis (VEGF, VEGFR2, COX2, IFNɣ). Moreover, the western blot data exhibited that Auraptene effect the protein expression of VCAM-1 and TNFR-1. Conclusions: Overall, this study shows that Auraptene significantly suppressed angiogenesis via down-regulation of VEGF, VEGFR2, VCAM-1, TNFR-1, COX-2 and up-regulation of IFNγ.
- 11 July 2020
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 393 (12) , 2315-2323
Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells
Nowadays, nanoparticle-based combination therapy has been emerging as huge innovation in cancer treatment. Here, we studied the effect of Stattic (STAT3 inhibitor) loaded in nanostructured lipid carriers (NLCs) on enhancing the efficacy, cytotoxicity, and induction of apoptosis of doxorubicin in B16F10 mouse melanoma cancer cell. The evaluation of Stattic-loaded NLCs has been done in terms of zeta potential, particle size, scanning electron microscope (SEM), and cellular uptake. MTT assay was applied to evaluate the cell proliferation. Apoptotic cell death and identification of early and late apoptosis were assessed by DAPI staining and Annexin V/PI staining, respectively. Real-time RT-PCR was applied to measure the effects of doxorubicin and/or Stattic on key apoptotic genes such as Bad, Survivin, HIF1, and STAT3. The Stattic formulated into NLCs shown mean particle size of 56 ± 7 nm which was confirmed by SEM. The IC50 values for Stattic and doxorubicin were 2.95 ± 0.52 μM and 1.21 ± 0.36 μM, respectively. Stattic-loaded NLCs diminished percent of cell proliferation from 68 ± 6.8 to 54 ± 3.7% (p < 0.05). Combinational treatment of the cells with Stattic-loaded nanoparticles and doxorubicin give rise to a significant increase in the percentage of apoptosis (p < 0.05). The study of gene expression profile has shown a remarkable decrease in anti-apoptotic gene, Survivin, along with smooth decline in HIF1 as angiogenesis intermediator and increase in Bad mRNA levels. Our results recommend that NLCs as novel technology have potent strategy to augment efficacy of current chemotherapeutic agent in melanoma cancer cells.
- 11 July 2020
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 393 (12) , 2315-2323
Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells
Nowadays, nanoparticle-based combination therapy has been emerging as huge innovation in cancer treatment. Here, we studied the effect of Stattic (STAT3 inhibitor) loaded in nanostructured lipid carriers (NLCs) on enhancing the efficacy, cytotoxicity, and induction of apoptosis of doxorubicin in B16F10 mouse melanoma cancer cell. The evaluation of Stattic-loaded NLCs has been done in terms of zeta potential, particle size, scanning electron microscope (SEM), and cellular uptake. MTT assay was applied to evaluate the cell proliferation. Apoptotic cell death and identification of early and late apoptosis were assessed by DAPI staining and Annexin V/PI staining, respectively. Real-time RT-PCR was applied to measure the effects of doxorubicin and/or Stattic on key apoptotic genes such as Bad, Survivin, HIF1, and STAT3. The Stattic formulated into NLCs shown mean particle size of 56 ± 7 nm which was confirmed by SEM. The IC50 values for Stattic and doxorubicin were 2.95 ± 0.52 μM and 1.21 ± 0.36 μM, respectively. Stattic-loaded NLCs diminished percent of cell proliferation from 68 ± 6.8 to 54 ± 3.7% (p < 0.05). Combinational treatment of the cells with Stattic-loaded nanoparticles and doxorubicin give rise to a significant increase in the percentage of apoptosis (p < 0.05). The study of gene expression profile has shown a remarkable decrease in anti-apoptotic gene, Survivin, along with smooth decline in HIF1 as angiogenesis intermediator and increase in Bad mRNA levels. Our results recommend that NLCs as novel technology have potent strategy to augment efficacy of current chemotherapeutic agent in melanoma cancer cells.
- 23 January 2020
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 41 (2)
Anti-inflammatory activity of emu oil-based nanofibrous scaffold through downregulation of IL-1, IL-6, and TNF-α pro-inflammatory cytokines
Background: Inflammation is one of the most important responses of the body against infection or disease, and it protects tissues from injury; however, it causes redness, swelling, pain, fever and loss of function. The aim of this present study was to evaluate the anti-inflammatory activity of emu oil (Eu) formulated nanofibrous scaffold in HFFF2 fibroblast cells. Materials and methods: Eu was formulated successfully in nanofibers through the electrospinning method. Besides, the morphological and structural properties of Eu nanofibres were evaluated using Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). The MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) was performed to evaluate the HFFF2 fibroblast cells’ viability. Also, real-time polymerase chain reaction (PCR) was used to evaluate the anti-inflammatory signaling pathway in treated HFFF2 cells with Eu nanofiber. Results: Our study showed that the Eu nanofiber increased the viability of fibroblast HFFF2 cells (p < 0.05). Also, the expression of interleukin1 ( IL1 ), IL6 and tumor necrosis factor- alpha ( TNF-α ) pro-inflammatory cytokines genes were significantly decreased in treated HFFF2 cells with Eu nanofiber (p < 0.05). Conclusions: In conclusion, Eu nanofiber scaffold potentially can reduce the inflammation process through downregulation of IL-1, IL-6 and TNF-α cytokines.
- 23 January 2020
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 41 (2)
Anti-inflammatory activity of emu oil-based nanofibrous scaffold through downregulation of IL-1, IL-6, and TNF-α pro-inflammatory cytokines
Background: Inflammation is one of the most important responses of the body against infection or disease, and it protects tissues from injury; however, it causes redness, swelling, pain, fever and loss of function. The aim of this present study was to evaluate the anti-inflammatory activity of emu oil (Eu) formulated nanofibrous scaffold in HFFF2 fibroblast cells. Materials and methods: Eu was formulated successfully in nanofibers through the electrospinning method. Besides, the morphological and structural properties of Eu nanofibres were evaluated using Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). The MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) was performed to evaluate the HFFF2 fibroblast cells’ viability. Also, real-time polymerase chain reaction (PCR) was used to evaluate the anti-inflammatory signaling pathway in treated HFFF2 cells with Eu nanofiber. Results: Our study showed that the Eu nanofiber increased the viability of fibroblast HFFF2 cells (p < 0.05). Also, the expression of interleukin1 ( IL1 ), IL6 and tumor necrosis factor- alpha ( TNF-α ) pro-inflammatory cytokines genes were significantly decreased in treated HFFF2 cells with Eu nanofiber (p < 0.05). Conclusions: In conclusion, Eu nanofiber scaffold potentially can reduce the inflammation process through downregulation of IL-1, IL-6 and TNF-α cytokines.